2025-09-18 17:51:10,044 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 17:51:10,731 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 17:51:11,929 - INFO - Starting document indexing process...
2025-09-18 17:51:11,930 - INFO - Processing file: 518-32 COVID-19 Retail HCP Market Tracking W4_Final Report_11.26.24.pptx
2025-09-18 17:51:12,799 - INFO - Processing file: AllText.CSV
2025-09-18 17:51:12,799 - WARNING - Unsupported file type: source_documents\AllText.CSV. Skipping.
2025-09-18 17:51:12,799 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022.xlsx
2025-09-18 17:51:18,033 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022blank.xlsx
2025-09-18 17:51:22,741 - INFO - Processing file: COVID-19 Market Tracking Workshop Deck_2.18.25_PRESENTATION .pptx
2025-09-18 17:51:22,951 - INFO - Processing file: Retail HCP Market Tracking W4_Final Report_11.26.24redacted.pptx
2025-09-18 17:51:23,861 - INFO - Adding 8666 document chunks to the collection.
2025-09-18 17:56:28,874 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 17:56:29,494 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 17:56:30,303 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 17:56:30,667 - INFO - Creating Gradio interface.
2025-09-18 17:56:30,860 - INFO - Launching Gradio app...
2025-09-18 17:56:31,328 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 17:56:31,330 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 17:56:33,263 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 17:56:35,297 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 17:56:35,863 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 17:57:49,149 - INFO - Querying vector store for: 'Are there any studies on malaria?'
2025-09-18 18:01:56,299 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:01:56,538 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 18:01:57,449 - INFO - Existing collection found.
2025-09-18 18:01:57,724 - INFO - Creating Gradio interface.
2025-09-18 18:01:57,916 - INFO - Launching Gradio app...
2025-09-18 18:01:58,437 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:01:58,438 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:02:00,389 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:02:02,456 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:02:02,964 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:02:37,578 - INFO - Querying vector store for: 'Are there any studies on COVID?'
2025-09-18 18:04:24,389 - INFO - Querying vector store for: 'Are there any studies on COVID?'
2025-09-18 18:04:26,122 - INFO - Querying vector store for: 'Are there any studies on COVID?'
2025-09-18 18:05:48,519 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:05:48,750 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 18:05:49,597 - INFO - Existing collection found.
2025-09-18 18:05:49,875 - INFO - Creating Gradio interface.
2025-09-18 18:05:50,069 - INFO - Launching Gradio app...
2025-09-18 18:05:50,552 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:05:50,554 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:05:52,511 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:05:54,576 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:05:55,112 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:06:24,045 - INFO - Querying vector store for: 'Are there any files referencing COVID?'
2025-09-18 18:08:42,448 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:08:42,684 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 18:08:43,483 - INFO - Existing collection found.
2025-09-18 18:08:43,729 - INFO - Creating Gradio interface.
2025-09-18 18:08:43,916 - INFO - Launching Gradio app...
2025-09-18 18:08:44,370 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:08:44,373 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:08:46,323 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:08:48,389 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:08:48,888 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:09:16,684 - INFO - Querying vector store for: 'Any files on COVID?'
2025-09-18 18:14:55,729 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:14:55,968 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 18:14:56,762 - INFO - Existing collection found.
2025-09-18 18:14:57,009 - INFO - Creating Gradio interface.
2025-09-18 18:14:57,194 - INFO - Launching Gradio app...
2025-09-18 18:14:57,648 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:14:57,651 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:14:59,583 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:15:01,640 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:15:02,153 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:15:23,343 - INFO - Querying vector store for: 'Any files on COVID?'
2025-09-18 18:15:23,474 - INFO - Retrieved context: []
2025-09-18 18:17:27,340 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:17:27,912 - INFO - Load pretrained SentenceTransformer: all-MiniLM-L6-v2
2025-09-18 18:17:28,933 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 18:17:29,393 - INFO - Creating Gradio interface.
2025-09-18 18:17:29,585 - INFO - Launching Gradio app...
2025-09-18 18:17:30,070 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:17:30,090 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:17:32,040 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:17:34,093 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:17:34,606 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:17:58,700 - INFO - Querying vector store for: 'Any files on COVID?'
2025-09-18 18:17:58,839 - INFO - Retrieved context: []
2025-09-18 18:45:17,546 - INFO - Querying vector store for: 'Any files on COVID?'
2025-09-18 18:45:17,564 - INFO - Retrieved context: []
2025-09-18 18:46:55,249 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:46:55,747 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 18:46:56,495 - WARNING - Xet Storage is enabled for this repo, but the 'hf_xet' package is not installed. Falling back to regular HTTP download. For better performance, install the package with: `pip install huggingface_hub[hf_xet]` or `pip install hf_xet`
2025-09-18 18:47:03,530 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 18:47:03,984 - INFO - Creating Gradio interface.
2025-09-18 18:47:04,188 - INFO - Launching Gradio app...
2025-09-18 18:47:04,631 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:47:04,631 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:47:06,613 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:47:08,660 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:47:09,155 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:51:06,495 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:51:07,195 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 18:51:08,955 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 18:51:09,396 - INFO - Creating Gradio interface.
2025-09-18 18:51:09,578 - INFO - Launching Gradio app...
2025-09-18 18:51:09,958 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:51:10,019 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:51:11,980 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:51:14,047 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:51:14,569 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:53:55,487 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:53:56,171 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 18:53:57,443 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 18:53:57,882 - INFO - Creating Gradio interface.
2025-09-18 18:53:58,074 - INFO - Launching Gradio app...
2025-09-18 18:53:58,540 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:53:58,542 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 18:54:00,503 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 18:54:02,555 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 18:54:03,079 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 18:55:37,324 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 18:55:37,960 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 18:55:39,176 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 18:55:39,607 - INFO - Starting document indexing process...
2025-09-18 18:55:39,608 - INFO - Processing file: 518-32 COVID-19 Retail HCP Market Tracking W4_Final Report_11.26.24.pptx
2025-09-18 18:55:40,459 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022.xlsx
2025-09-18 18:55:45,683 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022blank.xlsx
2025-09-18 18:55:50,510 - INFO - Processing file: COVID-19 Market Tracking Workshop Deck_2.18.25_PRESENTATION .pptx
2025-09-18 18:55:50,727 - INFO - Processing file: Retail HCP Market Tracking W4_Final Report_11.26.24redacted.pptx
2025-09-18 18:55:51,635 - INFO - Adding 8666 document chunks to the collection.
2025-09-18 19:10:37,406 - CRITICAL - Failed to add documents to ChromaDB: ValueError: Batch size of 8666 is greater than max batch size of 5461. The collection may be corrupted or the embedding dimensionality is mismatched. You may need to delete the collection folder manually.
2025-09-18 19:10:37,414 - INFO - Document indexing process completed successfully.
2025-09-18 19:10:37,416 - INFO - Creating Gradio interface.
2025-09-18 19:10:37,603 - INFO - Launching Gradio app...
2025-09-18 19:10:38,173 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:10:38,174 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:10:40,079 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 19:10:42,137 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 19:10:42,638 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 19:13:53,468 - INFO - Starting document indexing process...
2025-09-18 19:15:22,385 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 19:15:23,004 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 19:15:24,304 - WARNING - Collection not found or incompatible: Collection [digital_librarian_prod] does not exists. Recreating...
2025-09-18 19:15:24,741 - INFO - Starting document indexing process...
2025-09-18 19:15:24,742 - INFO - Processing file: 518-32 COVID-19 Retail HCP Market Tracking W4_Final Report_11.26.24.pptx
2025-09-18 19:15:25,553 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022.xlsx
2025-09-18 19:15:30,771 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022blank.xlsx
2025-09-18 19:15:35,885 - INFO - Processing file: COVID-19 Market Tracking Workshop Deck_2.18.25_PRESENTATION .pptx
2025-09-18 19:15:36,030 - INFO - Processing file: Retail HCP Market Tracking W4_Final Report_11.26.24redacted.pptx
2025-09-18 19:15:36,904 - INFO - Adding batch 1 of 5000 chunks...
2025-09-18 19:15:36,904 - INFO - Adding 5000 document chunks to the collection.
2025-09-18 19:24:02,869 - INFO - Adding batch 2 of 3666 chunks...
2025-09-18 19:24:02,870 - INFO - Adding 3666 document chunks to the collection.
2025-09-18 19:30:29,257 - INFO - Document indexing process completed successfully.
2025-09-18 19:30:29,260 - INFO - Creating Gradio interface.
2025-09-18 19:30:29,451 - INFO - Launching Gradio app...
2025-09-18 19:30:29,893 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:30:29,896 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:30:31,846 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 19:30:33,924 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 19:30:34,422 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 19:31:12,107 - INFO - Querying vector store for: 'Any files about COVID?'
2025-09-18 19:31:12,408 - INFO - Retrieved context: ['19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', '; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', '                   \xa0                                          \xa0                                                       \xa0                                                    \xa0                                          \xa0                                   \xa0                                                                                                        \xa0                         \xa0                     \xa0                                   \xa0                                \xa0                                      \xa0                                           \xa0                                                     \xa0                                                    \xa0                                               \xa0                                                   \xa0                                                                                                                                                                                                                                             ', '             \xa0                                          \xa0                                                       \xa0                                                    \xa0                                          \xa0                                   \xa0                                                                                                        \xa0                         \xa0                     \xa0                                   \xa0                                \xa0                                      \xa0                                           \xa0                                                     \xa0                                                    \xa0                                               \xa0                                                   \xa0                                                                                                                                                                                                                                                   ']
2025-09-18 19:31:12,707 - CRITICAL - Failed to get response from LLM: 'LLMClient' object has no attribute 'config'
2025-09-18 19:32:35,369 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 19:32:35,619 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 19:32:36,875 - INFO - Existing collection found.
2025-09-18 19:32:37,127 - INFO - Starting document indexing process...
2025-09-18 19:32:37,128 - INFO - Processing file: 518-32 COVID-19 Retail HCP Market Tracking W4_Final Report_11.26.24.pptx
2025-09-18 19:32:37,957 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022.xlsx
2025-09-18 19:32:43,191 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022blank.xlsx
2025-09-18 19:32:47,960 - INFO - Processing file: COVID-19 Market Tracking Workshop Deck_2.18.25_PRESENTATION .pptx
2025-09-18 19:32:48,107 - INFO - Processing file: Retail HCP Market Tracking W4_Final Report_11.26.24redacted.pptx
2025-09-18 19:32:48,988 - INFO - Adding batch 1 of 5000 chunks...
2025-09-18 19:32:48,989 - INFO - Adding 5000 document chunks to the collection.
2025-09-18 19:41:05,020 - INFO - Adding batch 2 of 3666 chunks...
2025-09-18 19:41:05,020 - INFO - Adding 3666 document chunks to the collection.
2025-09-18 19:47:19,116 - INFO - Document indexing process completed successfully.
2025-09-18 19:47:19,118 - INFO - Creating Gradio interface.
2025-09-18 19:47:19,360 - INFO - Launching Gradio app...
2025-09-18 19:47:19,918 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:47:19,918 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 19:47:21,864 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 19:47:23,924 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 19:47:24,473 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-18 19:47:54,434 - INFO - Querying vector store for: 'Are there any files on COVID?'
2025-09-18 19:47:54,699 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 's and use Paxlovid. \nAwareness of ICD-10 codes remains higher for COVID-19 than long COVID-19 and virtually all follow ICD-10 codes for COVID-19. \n \n\nProtocols in the Practice\n(Base: Have Protocols)\nAwareness of ICD-20 Codes \n\nBase: Aware of Codes \n\n\n\n\n82%\n54%\n85%\n\n52%\n\nBase: Aware of Codes \n\n\n\nMost of the COVID-19 treatment discussions are for Paxlovid, usually initiated by HCPs. \nOnce requested by patients/caregivers, it is granted most of the time. \nPotential drug-to-drug interactions are discussed most often during Paxlovid discussions (and is the top reason for not granting requests), though HCPs report discussing about its efficacy and side effects/contraindications less frequently this wave.  \nPast 3 Months …\nWho initiated?\n66% HCP\n34% Pt/CG\n\n73%\n(Among Those who Receive Requests)\n(n=230)\n         \n\nTop Reasons for Not Granting All Paxlovid Requests \n         \n\nTopics Typically Discussed During Paxlovid Discussions \nMar’24: LR: 62% HR: 83%\n(Among Total)\n(Among Total)\nNote: Quest']
2025-09-18 19:47:54,932 - CRITICAL - Failed to get response from LLM: 'llm_model_name'
2025-09-18 19:49:10,904 - INFO - Querying vector store for: 'Are there any files on COVID?'
2025-09-18 19:49:11,048 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 's and use Paxlovid. \nAwareness of ICD-10 codes remains higher for COVID-19 than long COVID-19 and virtually all follow ICD-10 codes for COVID-19. \n \n\nProtocols in the Practice\n(Base: Have Protocols)\nAwareness of ICD-20 Codes \n\nBase: Aware of Codes \n\n\n\n\n82%\n54%\n85%\n\n52%\n\nBase: Aware of Codes \n\n\n\nMost of the COVID-19 treatment discussions are for Paxlovid, usually initiated by HCPs. \nOnce requested by patients/caregivers, it is granted most of the time. \nPotential drug-to-drug interactions are discussed most often during Paxlovid discussions (and is the top reason for not granting requests), though HCPs report discussing about its efficacy and side effects/contraindications less frequently this wave.  \nPast 3 Months …\nWho initiated?\n66% HCP\n34% Pt/CG\n\n73%\n(Among Those who Receive Requests)\n(n=230)\n         \n\nTop Reasons for Not Granting All Paxlovid Requests \n         \n\nTopics Typically Discussed During Paxlovid Discussions \nMar’24: LR: 62% HR: 83%\n(Among Total)\n(Among Total)\nNote: Quest']
2025-09-18 19:49:11,049 - CRITICAL - Failed to get response from LLM: 'llm_model_name'
2025-09-18 19:49:41,382 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-18 19:49:41,609 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-18 19:49:42,962 - INFO - Existing collection found.
2025-09-18 19:49:43,226 - INFO - Starting document indexing process...
2025-09-18 19:49:43,227 - INFO - Processing file: 518-32 COVID-19 Retail HCP Market Tracking W4_Final Report_11.26.24.pptx
2025-09-18 19:49:44,120 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022.xlsx
2025-09-18 19:49:49,545 - INFO - Processing file: ATU Norms Benchmarks - HCP and Patients 2.16.2022blank.xlsx
2025-09-18 19:49:54,539 - INFO - Processing file: COVID-19 Market Tracking Workshop Deck_2.18.25_PRESENTATION .pptx
2025-09-18 19:49:54,744 - INFO - Processing file: Retail HCP Market Tracking W4_Final Report_11.26.24redacted.pptx
2025-09-18 19:49:55,653 - INFO - Adding batch 1 of 5000 chunks...
2025-09-18 19:49:55,653 - INFO - Adding 5000 document chunks to the collection.
2025-09-18 19:58:11,875 - INFO - Adding batch 2 of 3666 chunks...
2025-09-18 19:58:11,875 - INFO - Adding 3666 document chunks to the collection.
2025-09-18 20:04:20,620 - INFO - Document indexing process completed successfully.
2025-09-18 20:04:20,622 - INFO - Creating Gradio interface.
2025-09-18 20:04:20,874 - INFO - Launching Gradio app...
2025-09-18 20:04:21,464 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 20:04:21,465 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-18 20:04:23,374 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-18 20:04:25,445 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-18 20:04:25,999 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 08:13:41,773 - INFO - Querying vector store for: 'Are there any files referencing COVID?'
2025-09-19 08:13:42,408 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 's and use Paxlovid. \nAwareness of ICD-10 codes remains higher for COVID-19 than long COVID-19 and virtually all follow ICD-10 codes for COVID-19. \n \n\nProtocols in the Practice\n(Base: Have Protocols)\nAwareness of ICD-20 Codes \n\nBase: Aware of Codes \n\n\n\n\n82%\n54%\n85%\n\n52%\n\nBase: Aware of Codes \n\n\n\nMost of the COVID-19 treatment discussions are for Paxlovid, usually initiated by HCPs. \nOnce requested by patients/caregivers, it is granted most of the time. \nPotential drug-to-drug interactions are discussed most often during Paxlovid discussions (and is the top reason for not granting requests), though HCPs report discussing about its efficacy and side effects/contraindications less frequently this wave.  \nPast 3 Months …\nWho initiated?\n66% HCP\n34% Pt/CG\n\n73%\n(Among Those who Receive Requests)\n(n=230)\n         \n\nTop Reasons for Not Granting All Paxlovid Requests \n         \n\nTopics Typically Discussed During Paxlovid Discussions \nMar’24: LR: 62% HR: 83%\n(Among Total)\n(Among Total)\nNote: Quest']
2025-09-19 08:13:42,892 - CRITICAL - Failed to get response from LLM: 'google/gemma-3-27b'
2025-09-19 08:14:05,234 - INFO - Querying vector store for: 'Are there any files referencing COVID?'
2025-09-19 08:14:05,373 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 's and use Paxlovid. \nAwareness of ICD-10 codes remains higher for COVID-19 than long COVID-19 and virtually all follow ICD-10 codes for COVID-19. \n \n\nProtocols in the Practice\n(Base: Have Protocols)\nAwareness of ICD-20 Codes \n\nBase: Aware of Codes \n\n\n\n\n82%\n54%\n85%\n\n52%\n\nBase: Aware of Codes \n\n\n\nMost of the COVID-19 treatment discussions are for Paxlovid, usually initiated by HCPs. \nOnce requested by patients/caregivers, it is granted most of the time. \nPotential drug-to-drug interactions are discussed most often during Paxlovid discussions (and is the top reason for not granting requests), though HCPs report discussing about its efficacy and side effects/contraindications less frequently this wave.  \nPast 3 Months …\nWho initiated?\n66% HCP\n34% Pt/CG\n\n73%\n(Among Those who Receive Requests)\n(n=230)\n         \n\nTop Reasons for Not Granting All Paxlovid Requests \n         \n\nTopics Typically Discussed During Paxlovid Discussions \nMar’24: LR: 62% HR: 83%\n(Among Total)\n(Among Total)\nNote: Quest']
2025-09-19 08:14:05,374 - CRITICAL - Failed to get response from LLM: 'google/gemma-3-27b'
2025-09-19 08:18:46,987 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 08:18:47,271 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 08:18:48,617 - INFO - Existing collection found.
2025-09-19 08:18:49,598 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 08:18:49,598 - INFO - Creating Gradio interface.
2025-09-19 08:18:49,789 - INFO - Launching Gradio app...
2025-09-19 08:18:50,182 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 08:18:50,230 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 08:18:52,202 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 08:18:54,240 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 08:18:54,735 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 08:19:24,884 - INFO - Querying vector store for: 'Any files that reference COVID?'
2025-09-19 08:19:25,132 - INFO - Retrieved context: ['ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', '; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'available oral antiviral treatments for COVID-19?\nVirtually all HCPs feel that there is at least some unmet need with the currently available OAV. \n\n\n\nModified\nNote: Question modified in Oct’24 to a 6-point scale from a 7-point scale; not trackable\nResults generally consistent with prior wave\n\n\n82\nUnmet Need with Oral Antiviral Treatments (Ranked 1-3)\n\nBase: Believe There is Some Unmet Need with Oral Antiviral Treatments; Mar’24 (n=251), Oct’24 (n=240) \n\n. Which of the following represent unmet needs related to the oral antiviral treatments currently available for COVID-19? Please rank the top 5 unmet needs, where 1 is the primary unmet need and so forth. \nNeed for treatments with less drug-to-drug interactions remains as the primary unmet need with the currently available OAV, even more so than last wave. There are more HCPs this wave who see the need for prophylactic options for those exposed as a large unmet need. \nModified\nNote: Base updated in Oct’24, however, still trackable \nMod']
2025-09-19 08:19:25,580 - CRITICAL - Failed to get response from LLM: 'google/gemma-3-27b'
2025-09-19 08:21:03,539 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 08:21:03,794 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 08:21:04,889 - INFO - Existing collection found.
2025-09-19 08:21:05,177 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 08:21:05,178 - INFO - Creating Gradio interface.
2025-09-19 08:21:05,365 - INFO - Launching Gradio app...
2025-09-19 08:21:05,820 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 08:21:05,836 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 08:21:07,766 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 08:21:09,820 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 08:21:10,324 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 08:21:36,003 - INFO - Querying vector store for: 'Any files reference COVID? List them'
2025-09-19 08:21:36,275 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 'rceived as slightly more important than COVID-19. \nImportance of Vaccinations (Oct’24†) \nBase: Total Paxlovid-User HCPs; Oct’24 (n=250)\nB5. Thinking about your patients, how important is it for them to get regularly vaccinated for the following?\n\n\n\n\n\nModified\nNote: Question modified in Oct’24 to a 6-point scale from a 7-point scale; not trackable\n\nResults generally consistent with prior wave\n\n39\n\n\n\nPast 3 Month  COVID-19 Patient Load & Testing\nDetailed Findings\n\n\n40\nConsistent with prior waves, COVID-19 A12+ consultations make up 17% of Paxlovid writers’ patient loads, with about two-thirds of those testing positive for COVID-19.\nPatient Load (Past 3 Months)*\n\n\nBase: Total Paxlovid-User HCPs; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nSee slide notes for questions: S6-S9\n\nPatient Load in Past 3 Months*\nAge Distribution of COVID-19 Patients Treated/Consulted in Past 3 Months\n\n\n*Note: HCPs needed to see at least 10 A12+ COVID-19 patients in the past 3 months to qualif', 'evise and add, if needed\nPEP Indication: Current Questions\n27\n\n\nTASK: As a group, list all priority questions that should be covered within each of your topics. You will have 15 minutes.\nPart 1: \n\n\n\n\nGroup 1\nGroup 3\nGroup 2\nGroup 4\n28\n29\n\nGROUP BRAINSTORM: Prioritization\n\n\n\n\n\nGroup 1\nGroup 3\nGroup 2\nGroup 4\n30\n\n\n\n\n\n\n5 MIN BREAK\n\n\n31\n\nWhy are we looking to update attitudes?\n\nAttitudes Covered in Current ATU\n\nCurrent attitude lists are extensive (~40 attitudes tested) and most of them remain stable wave over wave.\nOur goal is to replace the current list with 10-15 long-term attitudes to track over time that is also relevant for prophylactic usage. We want the list to reflect attitudes that will be relevant for ensitrelvir adoption and will potentially change over time.\n\n\nGood example:\nCOVID-19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how C']
2025-09-19 08:24:27,867 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 08:43:51,609 - INFO - Querying vector store for: 'Any files that reference malaria?'
2025-09-19 08:43:51,764 - INFO - Retrieved context: ['Malaria HCP Zenket Insights Tracking Study Wave e\x0bQuantitative Research\n\nFinal Report | November 202e\n\n\n\n\n2\n\n\n\n\nTable of Contents\n\n\n\n3\nMonitors attitudes towards Malaria and diagnosis/treatment trends\nMonitors awareness, use and perceptions of currently available treatments, specifically focusing on Drugb\nAssesses awareness and perceptions of treatments for Malaria in development, including Druga\nIdentifies and quantifies value drivers that will help differentiate Druga at launch\xa0\nAssesses reactions to the Druga TPP\xa0\nIdentifies sources of information around Malaria, including sales reps\xa0\nAssesses manufacturer perceptions\nMonitors patients seen related to Malaria exposure and assesses interest and anticipated usage of a prescription medication that is approved for PEP only\nBackground and Objectives\nAs ABC Corp prepares for the launch of Druga, the team has implemented a Tracking Study among HCPs to monitor the evolving Malaria Zenket, including perceptions and knowledge about existing a', 'een in the past z months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new Malaria treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Drugb. \n25\n\n69%\nOf HCPs stay up to date on Malaria guidelines\n(Agree; Rated x-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\ne0%\nMost Preferred Info Source for New Malaria Treatments\nNational/Local KOLs\nColleagues \n20%\nez%\n\n\nEver Detailed on Drugb\n6t%\n\n+7\n6%\nEver Detailed on Druga\nt2%\nEver Detailed on Pemgarda\nNEW\n\n+te\n\n+9\n\n\n\nt\nKey Insights\x0b\nWhile about half of HCPs believe current Malaria variants are less of a concern, Malaria still puts a strain on healthcare professionals and there is still a need for more effective OAV treatments. \nMany agree that there is at least some unmet need with currently available OAV, especially treatments with less drug-to-drug interac', 'interactions remains as the priZeny unmet need with the currently available OAV, even more so than last wave. There are more HCPs this wave who see the need for prophylactic options for those exposed as a large unmet need. \nModified\nNote: Base updated in Oct’2e, however, still trackable \nModified\n\n\n\n\n\n83\n\n\n\nProducts in Development\nDetailed Findings\n\n84\nIn line with the prior wave, nearly tx% of HCPs report awareness of new treatments in development for Malaria. Druga is the top mentioned but still low at z%. \nUnaided Awareness of Malaria Treatments in Development/Soon to be Approved \n\nBase: Total Drugb-User HCPs; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nStz. Are you aware of any medications under development for the treatment of Malaria?\nSte. Please list the medications under development for the treatment of Malaria you are aware of. (OPEN END)\n2e%\nte%\n26%\n\n\nte%\n\n\n85\nAmong total HCPs, aided awareness is still highest for Druga, with z0% reporting awareness. \nAided', 'nts from contracting Malaria, following exposure to an infected person (post-exposure prophylaxis)? \nz8%\n7t%\n\nL/H Indicates a significant difference between risk level at the 90% confidence level \nL\n\nTypes of Patients would Receive PEP Indicated Oral Rx Medication \n\n108\n\n\n\nInfo Sources & Detailing\nDetailed Findings\n\n\n109\nConsistent with the prior wave, the CDC is the top preferred source for information about Malaria treatments. This wave, there are more HCPs who prefer colleagues and national/local KOLs. \nPreferred Info Sources\n\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nIz. What are your preferred sources of information to gain information about new treatments for Malaria? \n\n\n\n\n\n\n110\nOct’2z\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nJz. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nDrugb\nLage']
2025-09-19 08:45:07,502 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 08:45:50,170 - INFO - Querying vector store for: 'Give me the filename of a study that incorporated HCPs'
2025-09-19 08:45:50,342 - INFO - Retrieved context: ['                                          Total HCPs         102              0.46             0.9                                             0.68                            NaN                                NaN                                NaN                                       NaN                         NaN                                        NaN                                                     NaN                                                  NaN                                        NaN                                 NaN                                                                                                      NaN                       NaN                   NaN                                 NaN                              NaN                                    NaN                                         NaN                                                   NaN                                                  NaN                                       ', '                    Total HCPs         200              0.71               1                                             0.98                           0.91                               0.87                                NaN                                       NaN                         NaN                                        NaN                                                     NaN                                                  NaN                                        NaN                                 NaN                                                                                                      NaN                       NaN                   NaN                                 NaN                              NaN                                    NaN                                         NaN                                                   NaN                                                  NaN                                             NaN             ', '                                        Total HCPs          50              0.34             0.8                                             0.58                            NaN                                NaN                                NaN                                       NaN                         NaN                                        NaN                                                     NaN                                                  NaN                                        NaN                                 NaN                                                                                                      NaN                       NaN                   NaN                                 NaN                              NaN                                    NaN                                         NaN                                                   NaN                                                  NaN                                         ', '                 0.0           US                                                 Total HCPs         304              0.01            0.26                                              0.1                            NaN                                NaN                                NaN                                       NaN                         NaN                                        NaN                                                     NaN                                                  NaN                                        NaN                                 NaN                                                                                                      NaN                       NaN                   NaN                                 NaN                              NaN                                    NaN                                         NaN                                                   NaN                                                  Na']
2025-09-19 08:46:05,951 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 08:46:38,522 - INFO - Querying vector store for: 'Can you tell me if we ever did a study on Malaria? Answer yes or no. If yes, provide exact filename'
2025-09-19 08:46:38,693 - INFO - Retrieved context: ['Malaria HCP Zenket Insights Tracking Study Wave e\x0bQuantitative Research\n\nFinal Report | November 202e\n\n\n\n\n2\n\n\n\n\nTable of Contents\n\n\n\n3\nMonitors attitudes towards Malaria and diagnosis/treatment trends\nMonitors awareness, use and perceptions of currently available treatments, specifically focusing on Drugb\nAssesses awareness and perceptions of treatments for Malaria in development, including Druga\nIdentifies and quantifies value drivers that will help differentiate Druga at launch\xa0\nAssesses reactions to the Druga TPP\xa0\nIdentifies sources of information around Malaria, including sales reps\xa0\nAssesses manufacturer perceptions\nMonitors patients seen related to Malaria exposure and assesses interest and anticipated usage of a prescription medication that is approved for PEP only\nBackground and Objectives\nAs ABC Corp prepares for the launch of Druga, the team has implemented a Tracking Study among HCPs to monitor the evolving Malaria Zenket, including perceptions and knowledge about existing a', 'agree that they are a leader in developing treatments for Malaria? \n\n\n\nModified\nNote: Question modified in Oct’2e to a 6-point scale from a 7-point scale; not trackable\nResults generally consistent with prior wave\n\n\n\nNEW\nNEW\n\n\n113\nWhen forced to select one company, XYZ is still the top pharmaceutical company that is believed to be most likely to have a positive impact on treating and diagnosing patients with Malaria. \nPharmaceutical Company Most Likely to Make a Positive Impact on Treating & Diagnosing Patients with Malaria in the Next z Years\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nJ2. Which pharmaceutical company is most likely to make a positive impact on treating and diagnosing patients with Malaria in the next z years? \nNEW\n\n\n114\n\n\n\nAppendix \nDetailed Findings\n115\n\nDemographics & Practice Characteristics\n\n\n\n\n\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nSee slide notes for questions: Sz, Se,', 'ndents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nJz. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nDrugb\nLagevrio\n\nDruga\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Drugb. While detailing for Druga is still limited, t2% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see XYZ as a leader in developing treatments for Malaria, while they currently lack knowledge about ABC Corp.  \nExtent Manufacturer is a Leader in Developing Treatments for Malaria (Oct’2e†) \n\nBase: Total Respondents; Oct’2e (n=2x0)\nJt. For each of the following pharmaceutical companies, how much do you agree or disagree that they are a leader in developing treatments for Malaria? \n\n\n\nModified\nNote: Question modified in Oct’2e to a 6-point scale from a 7-point scale; not trackable\nResults generally consistent wi', 'nts from contracting Malaria, following exposure to an infected person (post-exposure prophylaxis)? \nz8%\n7t%\n\nL/H Indicates a significant difference between risk level at the 90% confidence level \nL\n\nTypes of Patients would Receive PEP Indicated Oral Rx Medication \n\n108\n\n\n\nInfo Sources & Detailing\nDetailed Findings\n\n\n109\nConsistent with the prior wave, the CDC is the top preferred source for information about Malaria treatments. This wave, there are more HCPs who prefer colleagues and national/local KOLs. \nPreferred Info Sources\n\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nIz. What are your preferred sources of information to gain information about new treatments for Malaria? \n\n\n\n\n\n\n110\nOct’2z\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’2z (n=z07), Oct’2z (n=z22), Zen’2e (n=2x7), Oct’2e (n=2x0)\nJz. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nDrugb\nLage']
2025-09-19 08:46:55,096 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 08:57:24,744 - INFO - Querying vector store for: 'Is there a file that references COVID? Please provide filename and extension.'
2025-09-19 08:57:24,965 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 'rceived as slightly more important than COVID-19. \nImportance of Vaccinations (Oct’24†) \nBase: Total Paxlovid-User HCPs; Oct’24 (n=250)\nB5. Thinking about your patients, how important is it for them to get regularly vaccinated for the following?\n\n\n\n\n\nModified\nNote: Question modified in Oct’24 to a 6-point scale from a 7-point scale; not trackable\n\nResults generally consistent with prior wave\n\n39\n\n\n\nPast 3 Month  COVID-19 Patient Load & Testing\nDetailed Findings\n\n\n40\nConsistent with prior waves, COVID-19 A12+ consultations make up 17% of Paxlovid writers’ patient loads, with about two-thirds of those testing positive for COVID-19.\nPatient Load (Past 3 Months)*\n\n\nBase: Total Paxlovid-User HCPs; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nSee slide notes for questions: S6-S9\n\nPatient Load in Past 3 Months*\nAge Distribution of COVID-19 Patients Treated/Consulted in Past 3 Months\n\n\n*Note: HCPs needed to see at least 10 A12+ COVID-19 patients in the past 3 months to qualif', '              \xa0                              \xa0                                  \xa0                                  \xa0                                         \xa0                           \xa0                                          \xa0                                                       \xa0                                                    \xa0                                          \xa0                                   \xa0                                                                                                        \xa0                         \xa0                     \xa0                                   \xa0                                \xa0                                      \xa0                                           \xa0                                                     \xa0                                                    \xa0                                               \xa0                                                   \xa0                                                                       ']
2025-09-19 08:57:24,972 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 404 Not Found"
2025-09-19 08:57:24,973 - CRITICAL - Failed to get response from LLM: Error code: 404 - {'error': {'message': 'Model "local-model" not found. Please specify a valid model.\n\nYour models:\n\ngoogle/gemma-3-27b\nopenai/gpt-oss-20b\ntext-embedding-nomic-embed-text-v1.5', 'type': 'invalid_request_error', 'param': 'model', 'code': 'model_not_found'}}
2025-09-19 08:57:42,863 - INFO - Querying vector store for: 'Is there a file that references COVID? Please provide filename and extension.'
2025-09-19 08:57:43,001 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', 'rceived as slightly more important than COVID-19. \nImportance of Vaccinations (Oct’24†) \nBase: Total Paxlovid-User HCPs; Oct’24 (n=250)\nB5. Thinking about your patients, how important is it for them to get regularly vaccinated for the following?\n\n\n\n\n\nModified\nNote: Question modified in Oct’24 to a 6-point scale from a 7-point scale; not trackable\n\nResults generally consistent with prior wave\n\n39\n\n\n\nPast 3 Month  COVID-19 Patient Load & Testing\nDetailed Findings\n\n\n40\nConsistent with prior waves, COVID-19 A12+ consultations make up 17% of Paxlovid writers’ patient loads, with about two-thirds of those testing positive for COVID-19.\nPatient Load (Past 3 Months)*\n\n\nBase: Total Paxlovid-User HCPs; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nSee slide notes for questions: S6-S9\n\nPatient Load in Past 3 Months*\nAge Distribution of COVID-19 Patients Treated/Consulted in Past 3 Months\n\n\n*Note: HCPs needed to see at least 10 A12+ COVID-19 patients in the past 3 months to qualif', '              \xa0                              \xa0                                  \xa0                                  \xa0                                         \xa0                           \xa0                                          \xa0                                                       \xa0                                                    \xa0                                          \xa0                                   \xa0                                                                                                        \xa0                         \xa0                     \xa0                                   \xa0                                \xa0                                      \xa0                                           \xa0                                                     \xa0                                                    \xa0                                               \xa0                                                   \xa0                                                                       ']
2025-09-19 08:58:51,468 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 09:19:04,751 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 09:19:05,007 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 09:19:06,361 - INFO - Existing collection found.
2025-09-19 09:19:07,310 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 09:19:07,310 - INFO - Creating Gradio interface.
2025-09-19 09:19:07,498 - INFO - Launching Gradio app...
2025-09-19 09:19:08,097 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 09:19:08,097 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 09:19:09,940 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 09:19:11,996 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 09:19:12,493 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 09:33:16,854 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 09:33:17,119 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 09:33:18,392 - INFO - Existing collection found.
2025-09-19 09:33:18,686 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 09:33:18,686 - INFO - Creating Gradio interface.
2025-09-19 09:33:18,882 - INFO - Launching Gradio app...
2025-09-19 09:33:19,372 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 09:33:19,372 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 09:33:21,303 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 09:33:23,355 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 09:33:23,865 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 10:07:06,644 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 10:07:07,153 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 10:07:08,348 - INFO - Existing collection found.
2025-09-19 10:07:08,644 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 10:07:08,644 - INFO - Creating Gradio interface.
2025-09-19 10:07:08,836 - INFO - Launching Gradio app...
2025-09-19 10:07:09,248 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:07:09,266 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:07:11,238 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 10:07:13,290 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 10:07:13,824 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 10:11:58,092 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 10:11:58,359 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 10:11:59,534 - INFO - Existing collection found.
2025-09-19 10:11:59,841 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 10:11:59,841 - INFO - Creating Gradio interface.
2025-09-19 10:12:00,064 - INFO - Launching Gradio app...
2025-09-19 10:12:00,586 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:12:00,664 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:12:02,620 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 10:12:04,667 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 10:12:05,204 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 10:12:46,583 - INFO - Querying vector store for: 'Anything on COVID?'
2025-09-19 10:12:46,822 - INFO - Retrieved context: ['19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ', '; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'o than last wave. There are more HCPs this wave who see the need for prophylactic options for those exposed as a large unmet need. \nModified\nNote: Base updated in Oct’24, however, still trackable \nModified\n\n\n\n\n\n83\n\n\n\nProducts in Development\nDetailed Findings\n\n84\nIn line with the prior wave, nearly 15% of HCPs report awareness of new treatments in development for COVID-19. Ensitrelvir is the top mentioned but still low at 3%. \nUnaided Awareness of COVID-19 Treatments in Development/Soon to be Approved \n\nBase: Total Paxlovid-User HCPs; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nS13. Are you aware of any medications under development for the treatment of COVID-19?\nS14. Please list the medications under development for the treatment of COVID-19 you are aware of. (OPEN END)\n24%\n14%\n26%\n\n\n14%\n\n\n85\nAmong total HCPs, aided awareness is still highest for Ensitrelvir, with 30% reporting awareness. \nAided Awareness of COVID-19 Treatments in Development/Undergoing Clinical Tria']
2025-09-19 10:14:58,667 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-09-19 10:21:10,932 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-09-19 10:21:11,185 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-09-19 10:21:12,373 - INFO - Existing collection found.
2025-09-19 10:21:12,671 - INFO - Vector store already contains documents. Skipping indexing.
2025-09-19 10:21:12,671 - INFO - Creating Gradio interface.
2025-09-19 10:21:12,865 - INFO - Launching Gradio app...
2025-09-19 10:21:13,281 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:21:13,301 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-09-19 10:21:15,292 - INFO - HTTP Request: GET http://localhost:7863/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-09-19 10:21:17,346 - INFO - HTTP Request: HEAD http://localhost:7863/ "HTTP/1.1 200 OK"
2025-09-19 10:21:17,845 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-09-19 10:21:43,534 - INFO - Performing keyword search for: 'COVID'
2025-09-19 10:46:18,633 - INFO - Performing keyword search for: 'HCP'
2025-09-19 10:46:27,052 - INFO - Performing keyword search for: 'Malaria'
2025-09-19 10:46:33,719 - INFO - Performing keyword search for: 'HCP'
2025-09-19 10:46:36,091 - INFO - Performing keyword search for: 'HCP'
2025-09-19 10:47:03,935 - INFO - Performing keyword search for: 'Malaria'
2025-09-19 11:42:39,259 - INFO - Querying vector store for: 'Are there any files referencing COVID?'
2025-09-19 11:42:40,466 - INFO - Retrieved context: ['; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nI3. What are your preferred sources of information to gain information about new treatments for COVID-19? \n\n\n\n\n\n\n110\nOct’23\nxxx\n\n\nTime Since Last Rep Detailing\nBase: Total Respondents; Jun’23 (n=307), Oct’23 (n=322), Mar’24 (n=257), Oct’24 (n=250)\nJ3. When was the last time you were detailed by a sales representative/medical liaison about the following product(s)?\nPaxlovid\nLagevrio\n\nEnsitrelvir\nSignificantly more than last wave, approximately 60% of HCPs have ever been detailed on Paxlovid. While detailing for Ensitrelvir is still limited, 12% report having been detailed on Pemgarda.  \n\n\n\n\n\nPemgarda\nNEW\n\n111\n\n\n\nManufacturer Perceptions\nDetailed Findings\n\n\n112\nMost HCPs see Pfizer as a leader in developing treatments for COVID-19, while they currently lack knowledge about Shionogi.  \nExtent Manufacturer is a Leader in Developing Treatments for COVID-19 (Oct’24†) \n\nBase: Total Respondents; Oct’24 (n=250)\nJ1. For each of the', 'ally related to their COVID-19 exposure. \nIf an oral Rx medication that is approved for PEP only becomes available, most are interested in prescribing, however, it is reserved more for HR patients, even though patients they have seen in the past 3 months skewed towards LR. \nAmong those\nWhile the CDC remains as the most preferred source for learning about new COVID-19 treatments, there is an uptick in those who prefer colleagues and national/local KOLs this wave. Significantly up from last wave, 60% of HCPs report having ever been detailed on Paxlovid. \n25\n\n69%\nOf HCPs stay up to date on COVID-19 guidelines\n(Agree; Rated 5-6)\n         \n         \n         \n         \nCDC\n76%\nFDA\n40%\nMost Preferred Info Source for New COVID-19 Treatments\nNational/Local KOLs\nColleagues \n20%\n43%\n\n\nEver Detailed on Paxlovid\n61%\n\n+7\n6%\nEver Detailed on Ensitrelvir\n12%\nEver Detailed on Pemgarda\nNEW\n\n+14\n\n+9\n\n\n\n1\nKey Insights\x0b\nWhile about half of HCPs believe current COVID-19 variants are less of a concern, COVI', '19 is now under control\nI am willing to try any new medication that has been proven to be effective for COVID-19\n\nBad example:\nWearing a mask in public places is a good idea\nI am concerned about how COVID-19 vaccinations/boosters were “fast-tracked”\nLife has never gone back to normal for me/my loved one post-COVID-19\n\n\n\n\n\nAttitudes:\nMad-Lib Exercise\n\n\nTASK: Fill out your Mad-Libs worksheets, either from an HCP or Consumer perspective\n\nExample: \n\nWhen I found out [my colleague] who I saw [at a conference] tested positive for COVID-19, I was [scared] because [I had a really bad case the last time]\n\n32\n\n\nTASK: The team will brainstorm attitudes, from the perspective of both HCPs and consumers.\nTask on Mural\n33\n34\n\nKey Themes from the Pre-workshop Exercise\nThe Results Are In!\n\n34\n\n\n\n\n\n\nTheme 2\nTheme 3\nTheme 4\nTheme 5\nTheme 6\nTheme 1\nHave we addressed all objectives? Does anything still need to be added or adjusted?\n\n\n\n\n\nAs a next step, Lieberman will take insights from today’s meeting and ']
2025-09-19 11:44:07,683 - INFO - HTTP Request: POST http://192.168.1.245:1234/v1/chat/completions "HTTP/1.1 200 OK"
2025-10-01 08:48:11,435 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-10-01 08:48:11,702 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-10-01 08:48:13,398 - INFO - Existing collection found.
2025-10-01 08:48:13,947 - INFO - Vector store already contains documents. Skipping indexing.
2025-10-01 08:48:13,947 - INFO - Creating Gradio interface.
2025-10-01 08:48:14,138 - INFO - Launching Gradio app...
2025-10-01 08:48:14,592 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-10-01 08:48:14,592 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-10-01 08:48:16,551 - INFO - HTTP Request: GET http://localhost:7860/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-10-01 08:48:18,613 - INFO - HTTP Request: HEAD http://localhost:7860/ "HTTP/1.1 200 OK"
2025-10-01 08:48:19,122 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-10-01 08:48:48,815 - INFO - Anonymized telemetry enabled. See                     https://docs.trychroma.com/telemetry for more information.
2025-10-01 08:48:49,016 - INFO - Load pretrained SentenceTransformer: thenlper/gte-large
2025-10-01 08:48:50,295 - INFO - Existing collection found.
2025-10-01 08:48:50,573 - INFO - Vector store already contains documents. Skipping indexing.
2025-10-01 08:48:50,573 - INFO - Creating Gradio interface.
2025-10-01 08:48:50,762 - INFO - Launching Gradio app...
2025-10-01 08:48:51,134 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-10-01 08:48:51,194 - INFO - HTTP Request: GET https://api.gradio.app/pkg-version "HTTP/1.1 200 OK"
2025-10-01 08:48:53,153 - INFO - HTTP Request: GET http://localhost:7860/gradio_api/startup-events "HTTP/1.1 200 OK"
2025-10-01 08:48:55,238 - INFO - HTTP Request: HEAD http://localhost:7860/ "HTTP/1.1 200 OK"
2025-10-01 08:48:55,726 - INFO - HTTP Request: GET https://api.gradio.app/v3/tunnel-request "HTTP/1.1 200 OK"
2025-10-01 08:48:56,142 - INFO - HTTP Request: GET https://cdn-media.huggingface.co/frpc-gradio-0.3/frpc_windows_amd64.exe "HTTP/1.1 200 OK"
